Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

December 10, 2025

Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe

Read more

December 4, 2025

New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta

Read more

December 1, 2025

Members of Egetis’ Leadership Team acquire shares in Egetis

Read more

Upcoming event

January 12-13, 2026

JP Morgan Healthcare week, San Francisco

Latest presentation

November 25, 2025

Q3 2025 report webcast (replay)

Latest Report

November 25, 2025

Interim report Q3 2025

Calendar and upcoming reports

January 12-13, 2026

JP Morgan Healthcare Week (San Francisco, CA)

February 26, 2026 (7:00am CET)

Year-end Report Q4 2025

March 8-11, 2026

Leerink Global Healthcare Conference (Miami, FL)

March 11-12, 2026

DNB Carnegie Healthcare Conference (Stockholm)

April 15-16, 2026

van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 29, 2026 (7:00am CEST)

Interim Report Q1 2026

May 6, 2026

Annual General Meeting

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]